Mirtastad (Mirtazapine)

Mirtazapine, the active ingredient in Mirtastad, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as a tablet for oral use. It is indicated for the management of major depressive disorder in adult patients, improving mood and functional outcomes.

GNH USA supplies Mirtastad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing EU‑origin quality for global markets. The company adheres to stringent regulatory standards and offers reliable logistics for timely delivery, including temperature‑controlled shipping where required.

Mirtazapine, a noradrenergic and specific serotonergic antidepressant, is used primarily in the treatment of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves overall mood. - Depressive disorder with insomnia: alleviates depressive symptoms while helping to restore normal sleep patterns. - Depressive disorder with anxiety: mitigates both depressive and anxiety symptoms, enhancing patient comfort.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness: often pronounced during initial therapy. - Increased appetite and weight gain: notable in many patients. - Dry mouth: mild to moderate discomfort. - Constipation: occasional gastrointestinal slowdown.

Serious or Rare Side Effects: - Agranulocytosis or neutropenia: severe reduction in white blood cells. - Severe hypersensitivity reactions: including rash, swelling, or anaphylaxis. - Suicidal thoughts or behavior: especially in early treatment phases. - Pancreatitis: rare inflammation of the pancreas. - Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating therapy, clinicians should consider several safety aspects.

- Dose titration: start low and increase gradually to minimize sedation. - Monitor weight: regular checks due to risk of weight gain. - Assess suicidality: watch for emergent suicidal thoughts, particularly early in treatment. - Caution in hepatic impairment: adjust dose if liver function is compromised. - Avoid abrupt discontinuation: taper slowly to reduce withdrawal symptoms. - Store at room temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Central nervous system depressants (e.g., benzodiazepines): additive sedation. - Strong anticholinergic agents: increased anticholinergic burden.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: potential for serotonin syndrome. - Warfarin: possible elevation of INR and bleeding risk. - Alcohol: enhanced central nervous system depression.